Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioScience Health Innovations (BHIC) Liabilities and Shareholders Equity (2019 - 2025)

BioScience Health Innovations (BHIC) has disclosed Liabilities and Shareholders Equity for 7 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 95.38% to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.2 million through Dec 2025, up 335.86% year-over-year, with the annual reading at $1.7 million for FY2025, 95.38% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $1.7 million at BioScience Health Innovations, down from $2.1 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $2.1 million in Q3 2025, with the low at $374.0 in Q2 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $470435.8, with a median of $94194.5 recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity plummeted 98.36% in 2021, then skyrocketed 6439.04% in 2022.
  • Over 5 years, Liabilities and Shareholders Equity stood at $96134.0 in 2021, then tumbled by 70.52% to $28343.0 in 2022, then skyrocketed by 229.49% to $93388.0 in 2023, then skyrocketed by 835.65% to $873788.0 in 2024, then surged by 95.38% to $1.7 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $1.7 million, $2.1 million, and $2.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.